Proteinase 3 sidesteps caspases and cleaves p21Waf1/Cip1/Sdi1 to induce endothelial cell apoptosis  by Pendergraft, William F. et al.
Kidney International, Vol. 65 (2004), pp. 75–84
CELL BIOLOGY – IMMUNOLOGY – PATHOLOGY
Proteinase 3 sidesteps caspases and cleaves p21Waf1/Cip1/Sdi1
to induce endothelial cell apoptosis
WILLIAM F. PENDERGRAFT, III, EARL H. RUDOLPH, RONALD J. FALK, JENNIFER E. JAHN,
MATTHIAS GRIMMLER, LUDGER HENGST, J. CHARLES JENNETTE, and GLORIA A. PRESTON
Department of Medicine, Division of Nephrology and Hypertension, Department of Pathology and Laboratory Medicine, University
of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and Max Planck Institute of Biochemistry, Martinsried, Germany
Proteinase 3 sidesteps caspases and cleaves p21Waf1/Cip1/Sdi1 to
induce endothelial cell apoptosis.
Background. Emerging data raise possibilities of a complex
and specific biologic role for leukocyte-derived proteases in
substrate processing and in signaling pathways. Neutrophil pro-
teinase 3 (PR3) is a caspase-like protease that enters endothelial
cells, cleaves nuclear factor-jB (NF-jB), and induces sustained
JNK activation, implying that the major cell cycle inhibitor p21
may be inactivated. Cleavage of p21 by caspase-3 is reported
to be required for endothelial cell apoptosis. We hypothesized
that PR3 may target p21.
Methods. Human umbilical vein endothelial cells (HUVEC)
were treated with or without PR3 (5 lg/mL) from 0 hours or up
to 8 hours, and analyzed for changes in cell cycle control proteins
by immunoblotting, immunofluorescence and flow cytometry.
Results. PR3 exposure resulted in cleavage of p21 between
Thr80 and Gly81, loss of nuclear p21 by cytoplasmic sequestra-
tion and depletion of p21 from cyclin/cyclin-dependent kinase
(CDK) complexes. Examination of cyclins D and E, p53, Rb,
and p27 revealed a largely nonproliferative expression profile.
Cells arrested in G1 were more susceptible to PR3 effects. We
examined inflamed human colonic tissue and found a fragment
similar in size to that generated by PR3 in HUVEC. Granzyme
B, a T-cell homologue of PR3 that cleaves caspase substrates,
also cleaves p21 between Asp62 and Phe63. A reported substrate
of granzyme B and caspases, Bid, is cleaved by PR3 signifying
commonality of substrates among these proteases.
Conclusion. A theme is developing that the granulocyte pro-
tease, PR3, is an exogenous caspase-like molecule that can
sidestep intracellular caspase functions at sites of inflammation.
The inflammatory response to tissue injury, due to ei-
ther trauma or infection, is primarily characterized by
leukocyte recruitment and extravasation. Although these
cells are critical to resolution of the injury, they are often
Key words: proteinase 3, p21, granzyme B, caspase, apoptosis, endothe-
lial cell.
Received for publication April 24, 2003
and in revised form May 23, 2003, July 2, 2003, and July 25, 2003
Accepted for publication August 8, 2003
C© 2004 by the International Society of Nephrology
responsible for the perpetuation of inflammation. A spe-
cific subset of leukocytes, namely neutrophils and mono-
cytes, possess granules containing millimolar amounts of
a variety of proteolytic enzymes that can be harmful to
tissues when released extracellularly [1]. Although pro-
tease inhibitors exist in plasma and in tissue fluid to offer
some defense, protease concentrations can overwhelm
the inhibitors and exist as unbound, active proteases at
high concentrations [2, 3].
Until recently, it was thought that the mechanism re-
sponsible for vascular endothelial cell injury was solely
due to the proteolytic degradation of extracellular ma-
trix molecules by these enzymes [4]. It is now becoming
clear that the mechanisms underlying tissue injury are
more complex than initially thought. We became inter-
ested in proteinase 3 (PR3) with the discovery that a
subset of vascular diseases is associated with anti-PR3
autoantibodies, termed antineutrophil cytoplasmic au-
toantibodies (ANCA) [5, 6]. ANCA are hypothesized to
bind to PR3 expressed on the surface of neutrophils and
monocytes, causing an exacerbation of the degranulation
process, resulting in excessive release of proteases,
thus contributing to endothelial injury and vasculitis
[7, 8]. PR3 is a granule serine protease that specif-
ically processes multiple biologic substrates, includ-
ing angiotensinogen [9], transforming growth factor-b1
(TGF-b1) [10], tumor necrosis factor-a (TNF-a) [11,
12], C1 inhibitor [13], and the transcription factor Sp1
[14].
PR3 can traverse the endothelial plasma membrane,
and, once internalized, induce apoptosis, implicating that
PR3 has diverse roles yet to be identified [15]. Cur-
rently what is known about PR3-mediated endothelial
cell apoptosis is that both the catalytically inactive and ac-
tive forms of PR3 induce death; however, the kinetics of
death are quite different. Inactive PR3 causes endothelial
cell apoptosis within 12 to 24 hours [15]. Although little
is known as to the specifics of this event, we found that a
100 amino acid region of the PR3 molecule is implicated
as responsible for death since a C-terminal fragment of
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PR3 induces apoptosis in a time frame similar to that of
the full-length inactive molecule.
Exposure of endothelial cells to active PR3 results in
cleavage and inactivation of the transcription factor, nu-
clear factor-jB (NF-jB), and sustained activation of JNK
[16]. Inhibition of caspases did not block the cleavage of
p65 NF-jB, and sequence analysis showed that the PR3
cleavage site was unique with respect to reported cas-
pase cleavage sites [17]. Death as a result of active PR3
treatment generally results in 4 to 6 hours.
These findings led us to hypothesize that neutrophils
and monocytes carry proteases that can function like cas-
pases. In support of this hypothesis are reports that PR3
can mimic caspase-2 and -3 by cleaving the Sp1 transcrip-
tion factor [18], and mimics caspase-1 in its ability to pro-
cess interleukin-1b (IL-1b) [12]. Such a function would
provide a unique mechanism of cross talk between leuko-
cytes and endothelial cells at sites of inflammation that
would impact both cytokine networks and cell viability.
While cleavage of NF-jB is required for apoptosis,
cleavage alone is not sufficient [16, 19]. These observa-
tions suggest that PR3-induced apoptosis may involve
cleavage of other, yet unidentified, substrates. A logical
candidate is p21Waf1/Cip1/Sdi1 (p21). p21 appears to be a
major determinant of cell fate [20]. It is known to inhibit
the activation of the apoptosis signal-regulating kinase,
c-Jun N-terminal kinase 1 (JNK 1), and caspase-3, and it
exerts an antagonistic effect on the mitochondrial path-
way of apoptosis [20–23]. In line with these data, we re-
ported earlier that exposure of endothelial cells to PR3
results in sustained activation of JNK [16], and for this
to occur, p21 inactivation would be implied, thus leading
to the proposal that PR3 may target p21. Furthermore,
the need for inactivation of p21 by caspase-3 cleavage
is reported to be required for endothelial cell apoptosis
[17].
The studies here determine if PR3-mediated cleavage
of p21 is a component of PR3-induced human umbilical
vein endothelial cell (HUVEC) apoptosis. Because p21
is an inhibitor of cyclin/cyclin-dependent kinase (CDK)
complexes responsible for cell cycle progression, we de-
termined what impact p21 cleavage could have on cell
cycle regulation in the presence of PR3. As an extension,
we investigated whether the T-cell protease granzyme
B, highly homologous in sequence and in structure to
PR3, had related substrate specificities. We also ad-
dressed the issue of whether this phenomenon is relevant
to sites of inflammation in vivo by examining tissue for
the presence of p21 cleavage products.
METHODS
Antibodies
Antibodies used were rabbit anti-Bid (FL-195), mouse
anti-cyclin D1 (HD11), mouse anti-cyclin E (HE12),
goat anti-ERK 1 (K-23), mouse anti-p21 (187), rabbit
anti-p21 (C-19), rabbit anti-p27 (N-20), rabbit anti-p27
(C-19), mouse anti-p53 (DO-1), rabbit anti-Rb (C-15)
(Santa Cruz Biotechnologies, Santa Cruz, CA, USA),
rabbit anti-WAF1 (Ab-5) (Calbiochem, La Jolla, CA,
USA), mouse anti-pRb (Pharmingen, San Diego, CA,
USA) mouse anti-Cip1/WAF-1 (Upstate Biotechnology,
Waltham, MA, USA) and rabbit anti-PR3 serum (kindly
donated by Wieslab AB, Lund, Sweden).
Culture and treatment of HUVEC
Pooled HUVEC (Clonetics, San Diego, CA, USA)
were cultured in endothelial basal medium (EBM) plus
endothelial growth medium (EGM) BulletKit supple-
ments (Clonetics) for four to eight doublings, but no
longer than 2 to 3 weeks. Triton X-100 was removed from
proteolytically active PR3 using an Extracti-Gel D Affini-
tyPak detergent-removing column (Pierce Chemical Co.,
Rockford, IL, USA). HUVEC monolayers were washed
with phosphate-buffered saline (PBS) and treated with
5 lg/mL of PR3 (Wieslab AB) at 37◦C. Of note, a second
source of commercial native PR3 purified from purulent
sputum was as efficient as purified neutrophil-derived
PR3 from whole blood (Elastin Products Co. Owensville,
MO, USA).
Because serum contains inhibitors of serine pro-
teases, all treatments were performed in serum-free
EBM medium without supplements. For competitive
broad-spectrum inhibition of caspases, YVAD-fmk (Cal-
biochem) was added at 100 nmol/L for 2 hours prior
to and during protease treatments as indicated. Cells
were treated with bleomycin (Sigma Chemical Co.,
St. Louis, MO, USA) prepared as described [24] at 1
lg/mL in standard growth medium 24 hours prior to pro-
tease treatments.
Assessment of 5-bromo-2′-deoxyuridine (BrdU)
incorporation and caspase-3 activation by flow
cytometry
BrdU was added to cell monolayers at 10 lmol/L
for 30 minutes prior to harvest. Attached and detached
cells were collected and combined for analysis. Apopto-
sis was quantitated as previously described [16]. Briefly,
detached and attached cells, treated for 8 hours with
5 lg/mL PR3 in serum-free medium, were combined,
fixed, and stained using the Fix and Perm Kit as directed
(Caltag, Burlingame, CA, USA). Apoptotic cells were
tagged using a-activated caspase-3 antibody plus fluo-
rescein isothiocyanate (FITC)-conjugated goat a-rabbit
secondary antibody (Dako, Carpinteria, CA, USA).
All labeled cells were analyzed by FACScan (Becton
Dickinson Immunocytometry Systems, San Jose, CA,
USA) linked to a Cicero/Cyclops system (Cytomation,
Fort Collins, CO, USA).
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Immunoblot analysis and immunocytochemistry
of HUVEC
Immunoblotting was performed as previously de-
scribed [16]. Briefly, diisopropylfluorophosphate (DFP)
was added to the treated HUVEC cultures 5 minutes
before cell lysis to irreversibly inhibit PR3 activity.
Cells were lysed at 3 × 106 cells/mL in hot Laemmli
protein lysis buffer [25], boiled (5 minutes), and son-
icated. Two × 105 cells were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotting. Primary antibodies
were prepared in 1% Blotto and incubated overnight
at 4◦C. Horseradish peroxidase-conjugated secondary
anti-mouse, anti-rabbit, or anti-goat antibodies (Chemi-
con, Temecula, CA, USA) were incubated for 2 hours
at room temperature, and visualized using West Pico
chemiluminescence substrate (Pierce Chemical Co.). For
immunocytochemistry, HUVEC were plated on 20 mm
cover slips at a density of 7.5 × 104 cells/slip and grown for
48 hours. Following treatments, cover slips were prepared
and visualized as described [15] using anti-p21 antibodies.
In vitro cleavage of p21, p27Kip1, and Bid
Recombinant hexahistidine-tagged human p21 was
metallopurified as described previously [26], immobi-
lized on 50 lL of Talon resin (Pierce Chemical Co.),
washed three times with PBS and incubated with ei-
ther 3 lg of PR3 or 10 U Granzyme B (Biomol
Research Laboratories, Plymouth Meeting, PA, USA)
for 30 minutes at 37◦C. Identical conditions were
used for Bid, which was immunopurified from HU-
VEC lysate (1 × 107 cells prepared by lysis in RIPA
buffer) using the anti-Bid antibody conjugated to pro-
tein A/G beads (Pierce Chemical Co.). Reactions were
terminated with hot 2× Laemmli sample buffer and
boiled for 5 minutes. Samples were subjected to
SDS-PAGE and visualized by Coomassie stain or further
evaluated by immunoblotting using N-terminus-specific
anti-p21 antibody. Fragments of p21 were sequenced
from polyvinylidine difluoride (PVDF) membranes by
Edman degradation by the Microprotein Core Facility at
the University of North Carolina at Chapel Hill.
Immunoprecipitations
For each sample, 1 × 106 HUVEC were scraped in
750 lL immunoprecipitation (IP) buffer [25 mmol/L
HEPES pH 7.5, 12.5 mmol/L MgCl2, 150 mmol/L KCl,
0.5% Igepal, 10 mmol/L dithiothreitol (DTT), 10% glyc-
erol and protease inhibitors], passed three times through
a 25 gauge syringe, nutated for 1 hour, and insoluble de-
bris removed by centrifugation at 5000 × g for 10 min-
utes at 4◦C. Two micrograms antibody for p21, cyclin D,
or an isotype-matched nonspecific control antibody was
added and incubated overnight at 4◦C. Fifty microliters
protein A/G slurry (Pierce Chemical Co.), washed three
times in IP buffer, was added to sample, incubated for
1 hour, pelleted by centrifugation at 3000 × g for 3 min-
utes at 4◦C, washed three times in IP buffer, and bound
proteins and antibodies were removed from beads with
1.5× Laemmli sample buffer, boiled for 5 minutes, and
subjected to SDS-PAGE and immunoblotting.
Human tissue preparation for immunoblotting
Small-sized pieces of affected colon tissue and tissue
distal to the inflamed site (∼1.0 cm3) were removed
from Crohn’s disease and ulcerative colitis patients dur-
ing operation and immediately frozen in liquid nitrogen.
Samples were homogenized in PBS or IP buffer con-
taining ethylenediaminetetraacetic acid (EDTA)-free
complete protease inhibitor cocktail (Roche Diagnos-
tics, Mannheim, Germany), and subjected to either im-
munoblotting or IP, respectively. Immunoblotting was
performed for PR3, p21, and truncated p21.
RESULTS
PR3 cleaves p21 after internalization
To determine if p21 is a substrate of internalized PR3,
endothelial cells exposed to PR3 were analyzed for p21
cleavage products. The serine protease inhibitor DFP was
added 5 minutes prior to cell lysis to prevent spurious
cleavage of proteins, as previously described [16]. Results
revealed a distinct cleavage product of p21 by 2 hours
that persisted through 8 hours, which was not present in
mock-treated control cells (Fig. 1A). The p21 cleavage
product, as detected by an N-terminus-specific antibody,
was approximately 10 kD. An increase in apoptosis over
mock-treated controls was observed (Fig. 1B) coincident
with p21 cleavage, and this death was consistent with our
previous findings [15]. To map the cleavage site, recombi-
nant human p21 was incubated with PR3 in vitro and re-
sultant peptide fragments were extracted and sequenced
(Fig. 1C). Sequence analysis revealed a unique cleavage
site on the p21 molecule between amino acids Thr80 and
Gly81. The identified site was unique from that reported
for caspase-3, which cleaves between amino acids Asp111
and Leu112 (Fig. 1D). From this set of experiments, we
conclude that PR3-mediated endothelial cell death in-
volves cleavage of p21 during activation of apoptosis.
PR3 cleavage of p21 does not require caspase activity
PR3 cleaves p21 in vitro; however, the possibility re-
mains that in vivo PR3 could activate some other cas-
pase that then cleaves p21 at or around this same site.
Therefore, we examined whether intracellular p21 cleav-
age could occur in the presence of the broad-spectrum
caspase inhibitor, YVAD-fmk, to determine if cas-
pases contribute to p21 cleavage events associated with
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Fig. 1. Proteinase 3 (PR3) cleaves p21 in endothelial cells. (A) Immunoblot analysis using an amino terminus-specific anti-p21 antibody reveals
a ∼10 kD p21 cleavage product in PR3-treated cells. (B) PR3-induced apoptosis is coincident with cleavage as determined by flow cytometric
analysis of apoptotic cells. (C) In vitro cleavage of p21. Recombinant human p21 was incubated with human PR3 and resultant peptide fragments
visualized by Coomassie stain of an 18% sodium dodecyl sulfate (SDS) gel. Cleavage product was extracted and sequenced (arrowhead). (D)
Schematic representation of p21 shows functional domains, the PR3 cleavage site (closed arrowhead) and the reported caspase-3 cleavage site
(open arrowhead).
PR3 exposure. We first confirmed that YVAD-fmk was
effective at inhibiting caspases in HUVEC (Fig. 2A). No
activated caspase-3–positive cells were detected in the
presence of the inhibitor. Immunoblot analysis revealed
that PR3 cleaved p21 in the presence or absence of
YVAD-fmk (Fig. 2B). These data confirm that PR3-
induced p21 cleavage is caspase-independent and sup-
ports indications that p21 is a substrate of PR3.
PR3-treated endothelial cells reside primarily
in G0/G1 stage of the cell cycle
We observed that shortly after PR3 exposure cells be-
gan to round up taking on a morphologic appearance
of mitotic cells with doublet-like cell clusters. We consid-
ered that this might be due to decreased attachment since
PR3 can cleave extracellular matrix proteins; however,
we repeatedly observed that cells were not apoptotic at
this point (data not shown). This change in morphology
could be indicative of PR3-induced cell cycle perturba-
tion; therefore, we determined if p21 cleavage was causing
premature entry into S phase. We measured the percent-
age of BrdU-incorporating S-phase cells by flow cytome-
try and found that no increase in BrdU incorporation was
observed as compared to mock-treated controls (data not
shown). These results would be in agreement with what
was observed after caspase-mediated p21 cleavage [17].
To further characterize changes in cell cycle status after
PR3 exposure, we investigated cell cycle regulating pro-
teins (Fig. 3A), including cyclin D and cyclin E. Cyclin D
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Fig. 2. Proteinase 3 (PR3)-mediated cleavage of p21 is caspase inde-
pendent in vivo. (A) YVAD-fmk, a pancaspase inhibitor, efficiently
inhibits caspases in human umbilical vein endothelial cells (HUVEC)
as determined by flow cytometric analysis of cells positive for active
caspase-3. (B) Cleavage of p21 in PR3-treated HUVEC is observed at
4 hours in cells pretreated for 2 hours with or without YVAD-fmk.
normally increases during G0/G1 reaching maximal lev-
els in S phase, and then remains elevated until mitosis.
Cyclin E normally starts to accumulate late in G0/G1,
peaks at the G1/S transition and then decreases during
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Fig. 3. Proteinase 3 (PR3)-treated endothe-
lial cells reside primarily in G0/G1 stage
of the cell cycle. (A) Immunoblot anal-
ysis of asynchronous cell populations of
human umbilical vein endothelial cells
(HUVEC) exposed to PR3, using antibod-
ies specific for cell cycle–related proteins. (B)
Enhanced PR3 effects on endothelial cells ar-
rested in G0/G1. Immunoblot analysis of cell
cycle control proteins in cells treated with
PR3 after 24 hours of bleomycin pretreat-
ment. Extracellular-related kinase-1 (ERK-1)
shown for standard protein loading. (C) Doc-
umentation that bleomycin is effective in in-
ducing growth arrest in HUVEC.
S phase [27]. In the PR3-treated cells, we found that cyclin
D levels were slightly decreased by 6 hours, while cyclin E
levels decreased by 2 hours. Because Rb is a substrate of
cyclin D/Cdk2 and cyclin E/Cdk2 at the G1/S transition,
we examined Rb phosphorylation. An accumulation of
hypophosphorylated Rb was more pronounced in PR3-
treated cells by 4 hours, indicative of early G1. p53 levels
decreased in PR3-treated cells by 2 hours. Overall, p27
levels were relatively unchanged, and notably, no cleav-
age product was detected using antibodies to either the
N- or C-terminus of the molecule. The activity of PR3 on
p21, without interfering with p27 levels in vivo, suggests
that PR3 regulates p21 functions, but appears not to dis-
rupt p27 in these cells. Of note, changes in protein abun-
dance at the 8-hour time point reflect cell death. Based on
these data, the majority of PR3-treated cells accumulate
in the early G1 stage of the cell cycle (i.e., before cyclin E
expression and Rb phosphorylation).
We noted from the data in Figure 1 that not all p21
molecules were cleaved after PR3 treatment. One expla-
nation would be that these cells were asynchronous and
only the cells in a particular stage of the cell cycle are
susceptible. We hypothesized that PR3 effects would be
exacerbated in cells forced to accumulate in the G0/G1
stage of the cell cycle. To test this, cells were exposed
to a chemotherapeutic drug, bleomycin, which activates
p21-induced cell cycle arrest, 24 hours prior to PR3 treat-
ment. Western blot analysis indicated that p21 was es-
sentially undetectable in growth-arrested cells after PR3
exposure (Fig. 4B), indicating that cleavage was enhanced
as compared to asynchronous cells (see Fig. 1A). En-
hanced reduction in cyclin D and E levels was observed
after exposure. As expected, Rb status in bleomycin-
treated cells was hypophosphorylated and unchanged
despite PR3 exposure, indicative of G0/G1. Bleomycin
treatment alone resulted in increased p53 also as ex-
pected, but was diminished after PR3 exposure. Why
this occurred will need to be investigated. Flow cyto-
metric analysis confirmed that cells were responsive to
bleomycin and were indeed arrested in the cell cycle
as demonstrated by lack of BrdU-positive S-phase cells
(Fig. 3C). From this set of experiments, we can con-
clude that susceptibility to PR3-induced effects is
enhanced in cells undergoing p21-induced cell cycle ar-
rest with accumulation in the early G1 phase of the cell
cycle.
PR3 alters subcellular localization of p21
Because the C-terminus of p21 contains a nuclear local-
ization sequence, and because the active p21 is bound to
nuclear cyclin/CDKs, we examined the intracellular dis-
tribution of p21 after PR3 exposure. Two hours after PR3
exposure, immunocytochemistry showed that immunore-
activity for p21 disappears from the nucleus (Fig. 4D to
F) as compared to untreated controls (Fig. 4A to C).
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Fig. 4. Functional consequences of proteinase 3 (PR3)-cleaved p21 in
human umbilical vein endothelial cells (HUVEC). Cells without (A to
C) or with (D to F) PR3 for 2 hours were probed for p21. (A and D)
20×, (B and E) 40×, and (C and F) 100× magnification. (B, C, E, and
F) Images shown with phase-contrast overlay. Immunofluorescence re-
veals loss of nuclear p21 in PR3-treated cells (representative of ∼50%
of cells). (G) Coimmunoprecipitations revealed that p21 is not com-
plexed with cyclin D/cyclin-dependent kinase (CDK)2 in PR3-treated
HUVEC. IP is immunoprecipitation; IB is immunoblot; and Ab is
antibody.
Since p21 was not detected in the nucleus after PR3 ex-
posure, we immunoprecipitated cyclin D, normally in the
nucleus, in order to determine if p21 was in the complex.
Full-length p21 was not observed complexed with cyclin
D in the PR3-treated group (Fig. 4G). We can surmise
that PR3 cleavage of p21 results in dissociation of p21
from the complex.
Analysis for commonality of substrates between PR3
and granzyme B
It is known that the T-cell serine protease granzyme B
induces cyclin A/Cdc2 and cyclin A/Cdk2 kinase activity,
and requires their induction in target cells for apopto-
sis to occur [28, 29]. Because PR3 cleaves p21 and has
high structural similarities to granzyme B (Fig. 5A), we
investigated whether granzyme B is capable of cleaving
p21 in vitro. Sequence analysis of p21 fragments revealed
a unique cleavage site on the molecule between amino
acids Asp62 and Phe63 (Fig. 5B). A schematic represen-
tation of p21 presents the cleavage sites for granzyme B,
PR3, and caspase-3 (Fig. 5C).
This work identified a substrate common to both
PR3 and granzyme B. To further demonstrate this com-
monality, we asked if PR3 could cleave a known sub-
strate of granzyme B, Bid [30]. Immunoblot analysis
for Bid revealed that in fact PR3 cleaves Bid in vitro,
although the fragment differed in size from that of
granzyme B (Fig. 5D). These findings support our hy-
pothesis that PR3 is a neutrophil homologue of T-cell
granzyme B.
Does a p21 cleavage product exist in inflamed
human tissue?
We hypothesized that p21 cleavage occurs during in-
flammation at sites of neutrophil infiltration. Free PR3
has been localized in inflamed tissue [2,3], and as a first
attempt to address this hypothesis we asked if a PR3-
like p21 cleavage product was present in inflamed tissue.
Tissue samples from patients with inflammatory bowel
disease provided a source to explore this question. Sec-
tions from a patient with Crohn’s disease removed dur-
ing colonic resection and anastomosis were homogenized
and the total protein was examined for the presence of
PR3. PR3 was detected and levels were highest in the in-
flamed section B (Fig. 6A). A distinct p21 fragment was
detected using the p21-specific antibody (Fig. 6B). The
size of the fragment is comparable to that generated in
HUVEC (Fig. 6C). Interestingly, the tissue labeled sec-
tion A was a small piece of bowel distal to the primary
site of inflammation (section B). Based on appearance
section A was assumed normal. However, the detection
of a p21 fragment in this section could be an indication
that some less obvious inflammation was occurring even
at this distal site. Next, we examined inflamed proximal
and transverse colon tissue obtained from a patient with
ulcerative colitis during a colonectomy. We were success-
ful in immunopurifying a p21 fragment of expected size
from tissue homogenates, using a p21-specific antibody
(Fig. 6D). This fragment was not detected in normal dis-
tal colon tissue.
It is known that caspase-3 cleaves p21 31 amino acids
downstream of the PR3 cleavage site. Although the frag-
ment appears to be generated by PR3 and not caspase-3,
based on size, sequencing of the fragment is necessary and
will need to be studied. Albeit, these data suggest that at
sites of inflammation there is the potential for PR3 to
cleave p21 in a manner similar to that observed in cell
culture studies.
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Fig. 5. A p21 cleavage product exists in inflamed human colonic tissue. Grossly normal (section A) and inflamed colon tissue (section B) were
removed from a patient with Crohn’s disease undergoing colonic resection and anastomosis. (A) Immunoblotting was performed for proteinase
3 (PR3). (B) Immunoblotting for p21 and truncated p21. (C) Human umbilical vein endothelial cells (HUVEC) with or without PR3 served as
controls for the PR3-generated p21 fragment. (D) Inflamed proximal and transverse colon tissue and grossly normal distal colon tissue was removed
from an ulcerative colitis patient undergoing colonectomy. p21 was immunoprecipitated from homogenized samples using either a non-specific
antibody (−) or an anti-p21 antibody (+), and immunoblotted for p21.
DISCUSSION
A critical role for PR3 may be to augment the effi-
ciency of caspase-dependent apoptotic events. We report
here that PR3 cleaves p21 and Bid, two very important
regulators of apoptosis, at signature sites. This function
of PR3 appears to sidestep the requirement for activa-
tion of the caspase cascade (Fig. 7). Our results support a
loss of function of p21 after PR3 cleavage based on the
lack of p21 in the nucleus, and the lack of detectable p21 in
complex with cyclin D [17]. We previously published that
PR3 is present in the cytoplasm and the nucleus after en-
dothelial cell entry [15] so it is likely that PR3 is cleaving
both nuclear and cytoplasmic p21. Cleavage of p21 by cas-
pases renders it inactive [17]. Even though PR3 cleaves
p21 31 amino acids upstream of caspase-3, the critical do-
mains of p21 are left intact suggesting that PR3-generated
fragments would be functionally similar to those gen-
erated by caspase-3. We postulate that PR3 performs
similar functions at sites of neutrophil and monocyte re-
cruitment in tissue based on our findings that the p21
fragment is present in inflamed bowel tissue, coincident
with detectable PR3.
It appears that the p21 molecule most susceptible to
PR3 cleavage is the form that is actively functioning as a
cell cycle inhibitor. In the presence of bleomycin, a cell
cycle inhibiting drug that induces active p21, the p21 lev-
els were ablated after PR3 treatment. It could be that
changes in p21 status, to its active inhibitory role, facil-
itate cleavage. Interestingly, PR3 treatment resulted in
reduced levels of cyclins D and E, indicative of the early
G0/G1 stage of the cell cycle, which is biochemically sim-
ilar to quiescence.
Although we detect roughly 15% to 20% apoptotic
HUVEC after PR3 exposure, there are several expla-
nations in which this percentage would be augmented.
One would be that the receptor necessary for PR3 entry
is only expressed on a subset of cells that is then up-
regulated during a stress response as in a focal inflamma-
tory setting in vivo [31–35]. A second explanation could
be that a cell cycle component is involved in PR3 effects.
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Fig. 6. Structurally similar proteinase 3 (PR3) and granzyme B cleave
p21 and Bid. (A) Ribbon diagrams of PR3 and granzyme B with
alpha-helical domains highlighted in red to illustrate structural simi-
larity between these two proteases [55, 56]. (B) Recombinant p21 was
incubated with granzyme B and resultant peptide fragments were visu-
alized by Coomassie stain of an 18% sodium dodecyl sulfate (SDS) gel.
Arrowhead indicates cleavage product that was excised for sequencing.
(C) Schematic representation of human p21 depicts the cleavage sites
of granzyme B (solid arrow), PR3 (closed arrowhead), and caspase-3
(open arrowhead). (D) Bid, immunopurified from human umbilical vein
endothelial cells (HUVEC) lysate, was incubated with granzyme B or
PR3. Both proteases cleaved Bid; however, cleavage products differed
in size (∗).
Our studies indicate that PR3-mediated cleavage of p21
is more pronounced when cells are exposed to the cell
cycle–perturbing chemotherapeutic drug, bleomycin.
PR3, also referred to as myeloblastin, expression ap-
pears to decrease during the course of normal myeloid
differentiation [36]. Coordinately, p21 expression in-
creases [37]. It appears that one role of PR3 is to
cleave and presumably inactivate p21 during the differ-
entiation process [38]. Furthermore, posttranscriptional
down-regulation of PR3 mRNA inhibits proliferation
and results in differentiation of myeloid progenitor cells
into mature polymorphonuclear leukocytes [36, 39].
The question arises as to how PR3 enters endothelial
cells and gains access to substrates in the cytoplasm of en-
Fig. 7. Schematic representation of proteinase 3 (PR3)-mediated p21
inactivation. At sites of inflammation, stimulated neutrophils and/or
monocytes undergo a respiratory burst releasing PR3, one component
of the granule constituents. PR3 is internalized by endothelial cells,
by an as yet undefined mechanism, and gains access to intracellular
substrates. PR3 cleaves p21 in a region known to be susceptible to cas-
pase 3 cleavage, although PR3 cleavage of p21 is caspase-independent.
Cleavage results in loss of function of p21 with nuclear exclusion and
activation of apoptosis. Because activation of the caspase cascade is not
required for p21 cleavage, the kinetics of apoptotic activation would be
accelerated. Subsequent phagocytosis of the apoptotic cell would aid
in the resolution of inflammation, as both the injured endothelial cells
and PR3 would be removed from the site.
dothelial cells. One possibility is that PR3 could be taken
up through receptor-independent mechanisms; however,
current knowledge strongly implies that PR3 is internal-
ized by a receptor-mediated mechanism [15, 16, 34]. In ad-
dition, Uehara et al [35] have reported that PR3 interacts
with protease-activated receptor-2 on the surface of oral
epithelial cells. Considering that electron micrographs of
endothelial cells exposed to PR3 revealed existence of
PR3 in the cytoplasm and in endocytic-like vesicles [15],
we can hypothesize that it escapes the endocytic vesicle.
This has been suggested by Witko-Sarsat et al [38] who
recently described a role for PR3 in myeloid differenti-
ation through PR3 cleavage of p21. They observed the
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colocalization of PR3 and p21 in the cytosol in these
cells. Their earlier findings that PR3 can exist in a plasma
membrane-mobilizable secretory vesicle [40] led them to
conclude that PR3 can escape from vesicles. Furthermore,
PR3 is functional at both low pH and pH 7. PR3 exists
in its native form as a functionally active holoenzyme
within the neutrophil primary granule at a pH of 3 [41].
Baici et al [42] showed that PR3 is characterized by a slow
gain of full activity with an increase of pH from 3.2 to
7.0. Since endothelial endosomes maintain an acidic pH
[43], the data indicate that PR3 is enzymatically stable in
this environment, and then becomes fully active once re-
leased by the endosome into the cytoplasm. In this case,
PR3 could escape from the endosome once internalized
just as other extracellular proteins are capable of doing
[44].
We compared substrate specificities in vitro between
PR3 and granzyme B, which is 37% homologous to
PR3, for the following reasons. First, granzyme B is a
highly characterized protease involved in cytotoxic T
lymphocyte-mediated apoptosis. Second, granzyme B,
like PR3, has been shown to be a caspase-like molecule in
that it also cleaves caspase substrates. Finally, granzyme
B-mediated apoptosis results in cyclin A-associated CDK
activity, which is required for successful killing [28, 29].
This increased activity led us to postulate that p21 func-
tion could be altered by granzyme B, and in vitro, this
is what was observed. Our observation that granzyme B
cleaves p21 offers a mechanism for how this could occur.
Our data and that of others demonstrate that truncation
of p21 renders it inactive, releasing CDKs from inhibition
by p21 [17, 38]. We suggest that PR3 is a neutrophil and
monocyte homologue of the T-cell protease granzyme B,
as supported by our findings that granzyme B cleaves p21
and that PR3 cleaves Bid [30].
PR3 and granzyme B may have evolved to combat
viruses that have developed ways of delaying apoptosis
to enable them to replicate and spread to uninfected cells.
It is important to note that although neutrophils are gen-
erally associated with defense against bacterial invasion,
they do play an important role in combating viral infec-
tion [45–48]. The granule secretory pathway is critical to
immune surveillance against aberrant cells. Moreover, it
is an intriguing concept that cleavage and/or inactivation
of p21 by PR3 or granzyme B could possibly be a mech-
anism of immune-mediated removal of neoplastic cells.
Recent clinical studies identified p21 expression as an in-
dicator of poor survival in prostate cancer [49–52], and
p21 has been reported to exert a protective effect against
chemotherapeutic drugs in other types of cancer [20, 53,
54]. Based on our findings indicating that cells blocked
in G0/G1 with bleomycin were more susceptible to PR3
effects, it may prove to be that tumor-directed PR3 treat-
ment would enhance the efficacy of current treatment
options.
Immune cells have evolutionarily acquired the capa-
bility to intervene into intracellular caspase cascades
through highly specialized proteases, thus providing
means to combat foreign microbes that override normal
apoptotic signals. This specificity for caspase substrates
constitutes an apoptotic effector mechanism of innate
and adaptive immune cell proteases. Our studies have
identified such a role for PR3 in normal diploid endothe-
lial cells, and we are actively engaged in identifying mech-
anism(s) of cellular entry.
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